FDA Denies Petition to Leave Testosterone Pellets off Difficult to Compound List

Drug Industry Daily
The FDA denied a petition from several pharmaceutical and outsourcing facilities urging the agency to keep implantable testosterone pellets off its Difficult to Compound list — but noted that so far it hasn’t made any moves to include it.

To View This Article:


Subscribe To Drug Industry Daily